Compare CPB & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPB | DVA |
|---|---|---|
| Founded | 1869 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Misc Health and Biotechnology Services |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 10.1B |
| IPO Year | 1994 | 2002 |
| Metric | CPB | DVA |
|---|---|---|
| Price | $21.12 | $150.65 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 16 | 4 |
| Target Price | $27.75 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 8.8M | 743.0K |
| Earning Date | 03-11-2026 | 02-02-2026 |
| Dividend Yield | ★ 7.42% | N/A |
| EPS Growth | ★ 6.35 | N/A |
| EPS | 1.13 | ★ 9.84 |
| Revenue | $10,253,000,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | N/A | $3.80 |
| Revenue Next Year | $0.97 | $3.04 |
| P/E Ratio | $18.61 | ★ $15.22 |
| Revenue Growth | 6.40 | ★ 6.46 |
| 52 Week Low | $20.87 | $101.00 |
| 52 Week High | $40.59 | $159.42 |
| Indicator | CPB | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 21.81 | 55.45 |
| Support Level | N/A | $146.05 |
| Resistance Level | $33.65 | $150.69 |
| Average True Range (ATR) | 0.67 | 4.35 |
| MACD | -0.35 | -1.56 |
| Stochastic Oscillator | 4.26 | 34.65 |
Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2025 (July year-end), snacks accounted for 43% of its revenue, followed by soup (27%), other simple meals (23%), and beverages (7%). Beyond its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and, most recently, Rao's (a deal that closed in 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.